Desvenlafaxine Succinate

CAS 448904-47-0

Interested in hearing more about this API?

DESVENLAFAXINE SUCCINATE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for major depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA.

About the API

Technology

Synthetic

Therapeutic category

Neurology-Psychiatry

Regulations

US DMF

Systematic Name

butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources. For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.